Entero Healthcare Solutions Limited (ENTERO) Fair Value & Analysis
Healthcare · IN · Market cap ₹51.4B
Fair value as of: Jun 29, 2026
Analysis
Entero Healthcare Solutions Limited (ENTERO) currently trades at ₹1,180, while our model-based Fair Value estimate is ₹645.04 — implying the stock looks roughly 45.4% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics. It also provides nebulizers, personal protective, hygiene and surgical consumable products, homecare medical devices, gloves and mobility equipment, digital thermometers. In addition, the company offers healthcare products, including pharmaceutical and nutraceutical products, vaccines, medical devices, such as orthopaedic implants and coronary stents, and hospital consumables comprising examination and surgical gloves, syringes, needles and sutures to hospitals, retail pharmacies, healthcare product manufacturers, and healthcare clinics. Entero Healthcare Solutions Limited was incorporated in 2018 an…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Entero Healthcare Solutions Limited (ENTERO) undervalued?
What is the fair value of ENTERO?
What is the quality score of ENTERO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.